StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BMO Capital on Biogen (BIIB): Apellis deal 'sets a clear path for further expansion in nephrology'
March 31, 2026 9:36 AM
BMO Capital analyst Evan Seigerman reiterated a Market Perform rating and $196.00 price target on Biogen (NASDAQ: BIIB)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
